The stock of NewAmsterdam Pharma Company NV (NASDAQ: NAMS) has decreased by -5.81 when compared to last closing price of 23.41. Despite this, the company has experienced a -6.61% fall in its stock price over the last five trading sessions. seekingalpha.com reported 2025-02-28 that New Amsterdam Pharma’s obicetrapib shows promise as a best-in-class CETP inhibitor, successfully lowering LDL-C in Phase 3 trials, with potential for significant market impact. The company plans to file for European approval in 2025, with ongoing trials potentially confirming additional cardiovascular benefits. Despite competition, obicetrapib’s oral administration and lack of side effects position it favorably against injectable PCSK9 inhibitors.
Is It Worth Investing in NewAmsterdam Pharma Company NV (NASDAQ: NAMS) Right Now?
Company’s 36-month beta value is -0.07.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 5 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for NAMS is 58.10M, and currently, short sellers hold a 7.47% ratio of that floaft. The average trading volume of NAMS on March 26, 2025 was 858.71K shares.
NAMS’s Market Performance
The stock of NewAmsterdam Pharma Company NV (NAMS) has seen a -6.61% decrease in the past week, with a 23.32% rise in the past month, and a -13.53% fall in the past quarter. The volatility ratio for the week is 4.16%, and the volatility levels for the past 30 days are at 6.30% for NAMS. The simple moving average for the last 20 days is -3.83% for NAMS stock, with a simple moving average of 9.69% for the last 200 days.
Analysts’ Opinion of NAMS
Many brokerage firms have already submitted their reports for NAMS stocks, with H.C. Wainwright repeating the rating for NAMS by listing it as a “Buy.” The predicted price for NAMS in the upcoming period, according to H.C. Wainwright is $48 based on the research report published on December 30, 2024 of the previous year 2024.
Scotiabank gave a rating of “Sector Outperform” to NAMS, setting the target price at $35 in the report published on March 14th of the previous year.
NAMS Trading at 1.18% from the 50-Day Moving Average
After a stumble in the market that brought NAMS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -19.20% of loss for the given period.
Volatility was left at 6.30%, however, over the last 30 days, the volatility rate increased by 4.16%, as shares surge +12.94% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -9.44% lower at present.
During the last 5 trading sessions, NAMS fell by -5.72%, which changed the moving average for the period of 200-days by +13.57% in comparison to the 20-day moving average, which settled at $22.94. In addition, NewAmsterdam Pharma Company NV saw -14.20% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NAMS starting from Topper James N, who purchase 4,005 shares at the price of $21.02 back on Mar 04 ’25. After this action, Topper James N now owns 3,012,434 shares of NewAmsterdam Pharma Company NV, valued at $84,203 using the latest closing price.
Kooij Louise Frederika, the Chief Accounting Officer of NewAmsterdam Pharma Company NV, sale 150,000 shares at $20.37 during a trade that took place back on Mar 04 ’25, which means that Kooij Louise Frederika is holding 15,000 shares at $3,055,500 based on the most recent closing price.
Stock Fundamentals for NAMS
Current profitability levels for the company are sitting at:
- -3.71 for the present operating margin
- 1.0 for the gross margin
The net margin for NewAmsterdam Pharma Company NV stands at -5.12. The total capital return value is set at -0.22.
Based on NewAmsterdam Pharma Company NV (NAMS), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -337.25. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is 305.7.
Currently, EBITDA for the company is -241.49 million with net debt to EBITDA at 3.22. When we switch over and look at the enterprise to sales, we see a ratio of 36.69. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.08.
Conclusion
In a nutshell, NewAmsterdam Pharma Company NV (NAMS) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
